CAS: 69034-12-4; 2-Chloro-5-(Trifluoromethyl)Pyrimidine

上下游产品

CAS号69034-11-3 Pyrimidine, 2-c... | CAS号3932-97-6 2,4-二氯-5-三氟甲基嘧啶 | CAS号7783-56-4 三氟化锑 | CAS号87-69-4 酒石酸 | CAS号1003845-08-6 2-氯嘧啶-5-硼酸频那醇酯 | CAS号2926-29-6 三氟代甲烷亚磺酸钠 | CAS号22536-61-4 2-氯-5-甲基嘧啶 | CAS号83767-80-0 5-(三氟甲基)-2-嘧啶酮

2,4-二氯-5-三氟甲基嘧啶置于溶剂黄146,锌体系中,用 四氢呋喃 作为反应溶剂,化学反应生成 2-氯-5-三氟甲基嘧啶
参考文献: Imidazopyridine Derivatives As Inhibitors Of Receptor Tyrosine Kinases[fr] Dérivés D'Imidazopyridine En Tant Qu'Inhibiteurs De Tyrosines Kinases Réceptrices
标题: Imidazopyridine Derivatives As Inhibitors Of Receptor Tyrosine Kinases[fr] Dérivés D'Imidazopyridine En Tant Qu'Inhibiteurs De Tyrosines Kinases Réceptrices
摘要:这项发明涉及新的双环杂环衍生物化合物,包括含有该化合物的药物组合物,以及利用该化合物治疗疾病,例如癌症.

专利信息

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:CN-1845906-A
优先权日:2003-09-05
标 题 :Selective synthesis of CF 3-substituted pyrimidines

专利号:CN-100465164-C
优先权日:2003-09-05
标题:CF3Selective synthesis of-substituted pyrimidines